Natera (NASDAQ: NTRA) — Company Overview, News & Financial Data
Natera is a biopharmaceutical company specializing in advanced genetic testing and diagnostics for prenatal health and cancer detection.
Natera
Natera is a global leader in cell-free DNA testing and genetic diagnostics, specializing in noninvasive prenatal testing, oncology, and organ health assessments. The company develops and commercializes molecular diagnostic services that analyze circulating cell-free DNA to detect genetic conditions, monitor cancer recurrence, and evaluate transplant organ rejection. Its core offerings include Panorama for noninvasive prenatal screening, Horizon for advanced carrier screening, Signatera for circulating tumor DNA minimal residual disease testing, and Prospera for organ transplant monitoring. Natera processes tests through its CAP-accredited and CLIA-certified laboratory facilities, partnering with clinicians, biopharmaceutical companies, and healthcare systems worldwide.
Snapshot
Operations
Products and/or services of Natera
- Women's Health Noninvasive Prenatal Screening: Noninvasive screening tests analyzing cell-free fetal DNA from maternal blood samples to assess chromosomal abnormalities, microdeletions, and single-gene conditions, processed in certified central laboratory facilities for obstetricians and expectant parents globally.
- Oncology Minimal Residual Disease Testing: Personalized molecular diagnostic assays tracking circulating tumor DNA in blood samples to detect residual disease, monitor treatment response, and identify disease recurrence across multiple solid tumor types in clinical and trial settings.
- Carrier Screening Services: Comprehensive panel tests analyzing parental DNA from blood or saliva samples to identify carrier status for inherited genetic disorders, supporting preconception and prenatal family planning decisions through certified laboratory reporting.
- Organ Health Rejection Assessment: Noninvasive donor-derived cell-free DNA blood tests designed to evaluate allograft injury and active rejection risk in kidney, heart, lung, and liver transplant recipients, enabling early clinical intervention by transplant care teams.
- Tissue and Tumor Genomic Profiling: Comprehensive genomic sequencing services performed on solid tumor tissue specimens to identify actionable mutations, genomic alterations, and biomarker profiles that guide targeted therapy selection for patients diagnosed with advanced malignancies.
- Biopharma Clinical Trial Partnerships: Specialized biomarker discovery, clinical trial support, and custom diagnostic development services provided to pharmaceutical partners to validate drug candidates and support global clinical development programs.
Natera executive team
- Dr. Matthew Rabinowitz Ph.D.Co-Founder & Executive Chairman
- Mr. Steven Leonard ChapmanCEO & Director
- Mr. John FeskoPresident & Chief Business Officer
- Mr. Michael B. Brophy M.B.A.Chief Financial Officer
- Mr. Solomon Moshkevich M.B.A.President of Clinical Diagnostics
- Mr. Jonathan Sheena M.Eng.Co-Founder & Director
- Ms. Olesya A. Anisimova CPAChief Accounting Officer
- Mr. Rishi KackerChief Technology Officer
- Mr. Eric A. Evans Ph.D.Chief Scientific Officer
- Mr. Daniel Rabinowitz L.L.M.Secretary & Chief Legal Officer